Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
The allowed patent application, titled 'Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives,' covers a unique series of methylone-inspired compounds, which are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders.
'With this second patent allowance for the EVM401 Series, Enveric continues to strengthen its position as a first-in-class developer of neuroplastogenic small-molecule therapeutics,' said Joseph Tucker, Ph.D., Director and CEO of Enveric. 'These patent-protected molecules are designed to capture the desirable neuroplasticity-promoting effects of methylone, while offering novel chemical structures that enable both strong IP protection and a potential path to repeat-dose outpatient care.'
Enveric's molecules share pharmacophoric elements with methylone, an MDMA analog recently associated with positive Phase 2 results for post-traumatic stress disorder (PTSD), but differ structurally in ways that render them patentable and proprietary. In contrast, methylone, a synthetic cathinone with structural limitations, has no available composition of matter patent exclusivity because its structure is in the public domain.
Enveric's differentiated benzodioxole analogs may offer similar therapeutic promise while potentially enabling a clearer regulatory and commercial path. The Company expects further preclinical testing will be required to evaluate safety, pharmacokinetics, and functional activity against PTSD and other psychiatric endpoints.
'The expansion of the EVM401 Series reflects Enveric's commitment to developing a deep pipeline of next-generation, non-hallucinogenic neuroplastogens that align with the scalability and safety needs of modern mental health treatment,' added Dr. Tucker. 'We believe this patent further positions Enveric at the forefront of the development of a new wave of targeted, accessible neuroplastogenic small-molecule drugs'
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
a minute ago
- Forbes
Will AGI Take Nvidia Stock To $300?
Could Nvidia stock (NASDAQ:NVDA) reach $300 in the next two years? There's a strong possibility. How? Consider this, just about three months ago, at the end of April 2025, Nvidia stock was trading at around $95 levels and presently trades at close to $174 per share. The stock is also up roughly 4x over the past two years. Let's look at valuations. Nvidia stock trades at about 40x consensus FY'26 earnings. Is this pricey?Not really. Especially if you consider the company's steadily expanding earnings, the long-growth runway for the artificial intelligence market, and Nvidia's formidable lead in the accelerated computing market. And if AGI (Artificial General Intelligence) becomes even partially realized over the next few years, the demand for high-performance computing could soar exponentially. In the scenario below, we use Nvidia's revenues, profitability, and valuation multiples to demonstrate a potential path to a $300 stock price. Nvidia CEO Jensen Huang delivers a keynote address at the Consumer Electronics Show (CES) in Las ... More Vegas, Nevada on January 6, 2025. Gadgets, robots and vehicles imbued with artificial intelligence will once again vie for attention at the Consumer Electronics Show, as vendors behind the scenes will seek ways to deal with tariffs threatened by US President-elect Donald Trump. The annual Consumer Electronics Show (CES) opens formally in Las Vegas on January 7, 2025, but preceding days are packed with product announcements. (Photo by Patrick T. Fallon / AFP) (Photo by PATRICK T. FALLON/AFP via Getty Images) More Demanding Workloads, AGI Can Drive Revenue Nvidia's revenues grew by almost 2x over the last 12 months, while posting an average annual growth rate of about 69% over the last three years, and the momentum can hold up. If Nvidia grows its sales at an average annual rate of over 60% for the next two years - its revenues could move from around $131 billion in FY'25 to around $334 billion by FY'27 or over 2.5x. There are several trends that could drive continued growth. While the initial AI models deployed by the likes of OpenAI in 2022 were largely text-based, models are increasingly multimodal, working with speech, images, video, and 3D calling for higher computing power and a larger number of GPU shipments. Besides this, Nvidia recently indicated that it received assurances from the Trump administration allowing it to resume sales of its H20 artificial-intelligence chip to China after facing a ban around April. This marks a significant win for the company, as it preserves access to a major and fast-growing AI market. More importantly, AI is expected to evolve from its current form - writing text, generating images - to more general intelligence. While the timeline is not certain, the goal is to get AI to reason, plan, learn new tasks without retraining. Artificial General Intelligence (AGI) could conduct scientific research, generate novel insights, or design entire products on its own. This could unlock breakthroughs and innovations across industries and some models suggest this could push global GDP growth from low single digits to over 20% annually. ((The Economist)) As the world moves closer to AGI, Nvidia could stands to benefit enormously. AGI systems are expected to require massive computational resources to train and run, considerably exceeding today's models, and Nvidia's GPUs are currently the industry standard for powering such workloads. AGI could not just be the next industrial revolution, it could be much bigger and Nvidia's chips could be right at the heart of it. Now the stock markets are often myopic and tend to extrapolate short-term trends for the long run. In Nvidia's case, the assumption is that demand growth and pricing power will hold up and profits will remain sizable as the generative AI wave advances. However, there are multiple risks and there remains a real possibility that the stock could see a sizable correction. We detail this possibility in our analysis of Nvidia Stock To Crash In 2025? Indeed we believe this broad range of upside and downside potential represents a simple fact: Nvidia is a volatile stock. Net Margins Will Remain Thick Combine this solid revenue growth with the fact that Nvidia's margins (net income, or profits after all expenses and taxes, calculated as a percent of revenues) are on an improving trajectory - they grew from levels of about 25% in FY'19 to over 51% in FY'25 as the company witnessed better economies of scale and a more favorable product mix skewed toward complex data center products. Software-related sales are also trending higher. We can assume that margins will remain flat at current levels as Nvidia's launch of pricier higher-end products such as the latest Blackwell chips are offset by potentially higher costs and competition in the lower-end of the market from the likes of AMD. With margins remaining flat and revenue rising 2.5x, we could see earnings rise 2.5x. Looking for an alternative AI play: Could AI contender AMD see a lift ahead of earnings? Strong Results Could Mean Earnings Multiples Hold Up Now, if earnings grow 2.5x, the PE multiple will shrink by 2.5x to levels of about 16x, assuming the stock price stays the same. But that's exactly what Nvidia investors are betting won't happen. If earnings expand 2.5x over the next few years, instead of the PE shrinking from a figure around 40x now to about 16x, a scenario where the PE metric stays at about 28x looks quite likely. For perspective, Apple - a company that is growing at low single-digits - trades at 30x. This would make the growth of Nvidia's stock by 1.7x within the next two years or so a real possibility, translating into a price of over $300 per share. What about the time horizon for this high-return scenario? In practice, it won't make much difference whether it takes two years or three, as long as Nvidia is on this revenue expansion trajectory, with margins holding up, the stock price could respond similarly. While Nvidia stock could have massive upside, it comes with risks and considerable volatility. On the other hand, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Yahoo
28 minutes ago
- Yahoo
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues. 'This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,' said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. 'Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.' Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said, 'By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.' For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347) in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
PAR Technology Corporation Releases Conference Call Information for Fiscal 2025 Second Quarter Financial Results
NEW HARTFORD, N.Y., July 28, 2025--(BUSINESS WIRE)--PAR Technology Corporation (NYSE: PAR) today announced that it will report its second quarter financial results on Friday, August 8, 2025. The results are scheduled to be released at 7:30 a.m. ET, followed by an investor presentation and conference call at 9:00 a.m. ET. The earnings conference call will be webcast live. To access the webcast, please visit the PAR Technology Investor Relations website at A recording of the webcast will be available on this site after the event. PAR Technology looks forward to your participation in this conference call. Please call Tiffani Temple at 315-738-0600 x 6325 with any questions. About PAR® Technology PAR Technology Corporation (NYSE: PAR) is a leading foodservice technology provider, powering a unified, purpose-built platform engineered to scale and adapt with brands at every stage of growth. Designed with flexibility and openness at its core, PAR's solutions—spanning point-of-sale, digital ordering, loyalty, back-office, payments, and hardware—integrate with others, yet deliver maximum impact as a unified system. With intentional innovation at the forefront, PAR's solutions streamline operations, drive higher engagement, and strengthen guest experiences in over 130,000 restaurants globally and 26,000 national c-store retailers. To learn more, visit or connect with us on social media. View source version on Contacts Christopher R. Byrnes (315) 743-8376cbyrnes@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
